ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Michigan » Cardiovascular Disease

Top Cardiovascular Disease Prescribers in Michigan

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
NARSIMHA GOTTAM M.D.

Cardiovascular Disease

10,452

$582K

490
350 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

17%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 22%

$56
Average prescription price

Avg: $73

MAHIR ELDER MD

Cardiovascular Disease

9,454

$464K

652
324 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

13%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 22%

$49
Average prescription price

Avg: $73

STEVEN KOROTKIN MD

Cardiovascular Disease

8,953

$734K

743
700 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

3%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 22%

$82
Average prescription price

Avg: $73

SAMIR DABBOUS M.D.

Cardiovascular Disease

8,917

$568K

953
805 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

28%
prescriptions for brand name drugs

Avg: 22%

$64
Average prescription price

Avg: $73

DURGADAS NARLA MD

Cardiovascular Disease

8,196

$713K

660
609 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

4%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 22%

$87
Average prescription price

Avg: $73

THOMAS LALONDE MD

Cardiovascular Disease

8,039

$584K

689
642 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 22%

$73
Average prescription price

Avg: $73

THEODORE SCHREIBER MD

Cardiovascular Disease

7,915

$742K

894
767 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

3%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 22%

$94
Average prescription price

Avg: $73

JEFFREY HARRIS D.O.

Cardiovascular Disease

7,820

$651K

767
641 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

2%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 22%

$83
Average prescription price

Avg: $73

MARK RASAK DO

Cardiovascular Disease

7,657

$668K

653
498 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

8%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 22%

$87
Average prescription price

Avg: $73

DAVID GRAHAM MD

Cardiovascular Disease

7,545

$580K

399
370 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

8%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 22%

$77
Average prescription price

Avg: $73

JAVAID BASHIR M.D.

Cardiovascular Disease

7,147

$650K

345
182 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

51%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 22%

$91
Average prescription price

Avg: $73

STEPHEN PECK M.D.

Cardiovascular Disease

6,858

$564K

869
756 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 22%

$82
Average prescription price

Avg: $73

ARIF HAKIM M.D.

Cardiovascular Disease

6,676

$227K

433
104 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

76%
patients receiving schedule three controlled substances

Avg: 2%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

18%
prescriptions for brand name drugs

Avg: 22%

$34
Average prescription price

Avg: $73

SRINIVASAN DHATREECHARA N M.D.

Cardiovascular Disease

6,450

$464K

375
295 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 22%

$72
Average prescription price

Avg: $73

LYNN MILLER MD

Cardiovascular Disease

6,376

$536K

635
599 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 22%

$84
Average prescription price

Avg: $73

NARSINGH GUPTA MD

Cardiovascular Disease

6,304

$479K

388
284 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

22%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 22%

$76
Average prescription price

Avg: $73

ABDUL CHOUDHRY M.D.

Cardiovascular Disease

6,290

$285K

235
149 are 65+

9%
patients receiving schedule two controlled substances

Avg: 0%

35%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

17%
prescriptions for brand name drugs

Avg: 22%

$45
Average prescription price

Avg: $73

JEROME KUHNLEIN M.D.

Cardiovascular Disease

6,244

$423K

691
603 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 22%

$68
Average prescription price

Avg: $73

RODOLJUB DIMITRIJEVIC M.D.

Cardiovascular Disease

6,089

$324K

329
302 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

11%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 22%

$53
Average prescription price

Avg: $73

LARRY ROTHSTEIN DO

Cardiovascular Disease

6,066

$226K

367
308 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

15%
prescriptions for brand name drugs

Avg: 22%

$37
Average prescription price

Avg: $73

KIRITKUMAR PATEL M.D.

Cardiovascular Disease

5,905

$442K

797
717 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 22%

$75
Average prescription price

Avg: $73

NISHIT CHOKSI M.D.

Cardiovascular Disease

5,888

$608K

762
670 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

30%
prescriptions for brand name drugs

Avg: 22%

$103
Average prescription price

Avg: $73

JAPHET JOSEPH M.D.

Cardiovascular Disease

5,661

$423K

587
516 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 22%

$75
Average prescription price

Avg: $73

DILLIP ARORA M.D

Cardiovascular Disease

5,657

$376K

794
690 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

2%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 22%

$67
Average prescription price

Avg: $73

HARESH JANI M.D.

Cardiovascular Disease

5,504

$423K

315
221 are 65+

5%
patients receiving schedule two controlled substances

Avg: 0%

17%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 22%

$77
Average prescription price

Avg: $73

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank